Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP710097.RAMOHFo5M548N3-VyoH2UTdDMr2GCuJ1t2OTrNZuG63qE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP710097.RAMOHFo5M548N3-VyoH2UTdDMr2GCuJ1t2OTrNZuG63qE130_assertion type Assertion NP710097.RAMOHFo5M548N3-VyoH2UTdDMr2GCuJ1t2OTrNZuG63qE130_head.
- NP710097.RAMOHFo5M548N3-VyoH2UTdDMr2GCuJ1t2OTrNZuG63qE130_assertion description "[Although anti-CD19 CAR T cells are at an early stage of development, the potent antigen-specific activity observed in patients suggests that infusions of anti-CD19 CAR T cells might become a standard therapy for some B-cell malignancies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP710097.RAMOHFo5M548N3-VyoH2UTdDMr2GCuJ1t2OTrNZuG63qE130_provenance.
- NP710097.RAMOHFo5M548N3-VyoH2UTdDMr2GCuJ1t2OTrNZuG63qE130_assertion evidence source_evidence_literature NP710097.RAMOHFo5M548N3-VyoH2UTdDMr2GCuJ1t2OTrNZuG63qE130_provenance.
- NP710097.RAMOHFo5M548N3-VyoH2UTdDMr2GCuJ1t2OTrNZuG63qE130_assertion SIO_000772 23546520 NP710097.RAMOHFo5M548N3-VyoH2UTdDMr2GCuJ1t2OTrNZuG63qE130_provenance.
- NP710097.RAMOHFo5M548N3-VyoH2UTdDMr2GCuJ1t2OTrNZuG63qE130_assertion wasDerivedFrom befree-20150227 NP710097.RAMOHFo5M548N3-VyoH2UTdDMr2GCuJ1t2OTrNZuG63qE130_provenance.
- NP710097.RAMOHFo5M548N3-VyoH2UTdDMr2GCuJ1t2OTrNZuG63qE130_assertion wasGeneratedBy ECO_0000203 NP710097.RAMOHFo5M548N3-VyoH2UTdDMr2GCuJ1t2OTrNZuG63qE130_provenance.